John S. Montalbano is Director at AbCellera Biologics Inc. (ABCL). They have made 9 open-market trades across 1 company since 2021, most recently 2026-08-18.
CIK 0001834423
9 open-market purchases totalling $1.2M since 2021, never a sale. Across 8 scored buys the stock is up 21.8% at ninety days, and 18.3 points ahead of the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ABCL | 251,000 | $3.1M |
Shares reported on the most recent Form 4, priced at the 2026-08-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 67% | 50% |
| Avg Move | +6.5% | +10.8% | +21.8% |
| Alpha | +5.5% | +10.2% | +18.3% |
| Scored | 9 | 9 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABCL | BUY | 2026-08-18 | 2026-08-18 | $11.03 | $110K | -2.0% | +9.9% | — |
| ABCL | BUY | 2026-05-14 | 2026-05-18 | $4.77 | $95K | +51.7% | +33.6% | +174.8% |
| ABCL | BUY | 2025-11-26 | 2025-11-26 | $3.57 | $179K | -1.3% | -4.0% | -13.7% |
| ABCL | BUY | 2025-03-10 | 2025-03-10 | $2.30 | $115K | +7.2% | -2.3% | +13.1% |
| ABCL | BUY | 2025-03-06 | 2025-03-07 | $2.34 | $140K | +2.6% | -12.0% | +1.7% |
| ABCL | BUY | 2023-11-06 | 2023-11-08 | $4.58 | $137K | +9.3% | +15.7% | +23.0% |
| ABCL | BUY | 2022-03-04 | 2022-03-04 | $8.54 | $171K | +0.6% | +23.2% | -8.6% |
| ABCL | BUY | 2022-03-01 | 2022-03-03 | $9.05 | $181K | -12.9% | +16.7% | -12.6% |
| ABCL | BUY | 2021-08-16 | 2021-08-17 | $17.23 | $103K | +3.5% | +16.6% | -3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.